Safety and Immunogenicity of Biologic Therapy in Inflammatory Bowel Disease

Publication date: July 2017 Source:Hospital Medicine Clinics, Volume 6, Issue 3 Author(s): Vera DenmarkTeaser Inflammatory bowel diseases, Crohn disease, and ulcerative colitis are complex multifactorial diseases that involve the interaction between innate and adaptive immunity. Tumor necrosis factor α is a potent proinflammatory cytokine with pleiotropic effects on cells of the innate and adaptive immune systems. Medical therapies that block tumor necrosis factor α have changed the clinical management of inflammatory bowel disease. This review discusses immunogenicity and safety of these agents as well as strategies to reduce infectious complications. In addition, new biologic therapies that inhibit various elements in the leukocyte infiltration process and others that target proinflammatory cytokines are addressed.
Source: Hospital Medicine Clinics - Category: Internal Medicine Source Type: research